New Publication Guidance on gene replacement therapy in Spinal Muscular Atrophy: a Canadian perspective

The NMD4C is proud to announce that a Guidance on gene replacement therapy in Spinal Muscular Atrophy: a Canadian perspective has been accepted for publication by the Canadian Journal of Neurological Sciences. Notably this consensus statement is authored by NMD4C members Drs. Maryam Oskoui, Hernan Gonorazky, Hugh McMillan, James Dowling, Reshma Amin, Cynthia Gagnon, and Kathryn Selby.

This publication is the first significant research output of the NMD4C, and is a product of the network’s development, dissemination, and implementation of clinical guidelines working group. The working group invited pediatric neuromuscular clinical experts from across the country to provide feedback and direction in adapting existing consensus statements on gene replacement therapy in SMA to the Canadian context.

“It is an exciting time for the neuromuscular field with the advancement of gene therapies. It is our duty as neuromuscular specialists to advocate for safe, equitable, and transparent access to these treatments for all Canadians. We hope that through this consensus we can help inform the application, indication and use of gene replacement therapy in Spinal muscular atrophy.”

– Dr. Hernan Gonorazky.

You can find the publication here.

With three SMA therapies now commercially available in Canada, the working group set out to provide guidance by adapting a set of European consensus statements to a Canadian context and highlighting areas of future need for gene replacement therapy in SMA in Canada. The original publication  from an ad-hoc group of 13 European SMA experts who published a set of consensus statements on the use of gene replacement therapy in SMA using a Delphi consensus process.

The NMD4C will continue to work towards its knowledge translation (KT) goals to improve care standards, train the next generation of neuromuscular researchers and clinicians, and strengthen research infrastructure for better research and more treatments.

GuidanceSMApaper

Read next...

2024 NMD4C Annual Meeting

NMD4C Welcomed Investigators to Annual Meeting in Calgary

Thank you to our investigators who attended the Annual NMD4C Meeting on September 27th in Calgary! Our meeting program consisted of presentations from pillar and task leads which highlighted their groups’ achievements and progress made to date.

LEARNMD logo

NMD4C Launch Educational Platform LEARNMD

LEARNMD is an online educational platform offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide.

CNDR logo4x3

October 2024 Updates from the Canadian Neuromuscular Disease Registry

The Canadian Neuromuscular Disease Registry (CNDR) is pleased to share updates on several exciting initiatives this fall!

2025 early career awards

2025 Annual NMD4C Early-Career Awards Open for Applications

We are excited to announce the opening of our third annual early-career awards competition!

Canadian neuromuscular fellows attend the WCNMC in Calgary, AB.

NMD4C Provides Opportunity for Neuromuscular Fellows to Build Clinical Network at National Meeting

We are pleased to share that this fall we provided an opportunity for clinical neuromuscular fellows to attend NMD4C’s annual meeting and the Western Canadian Neuromuscular Conference (WCNMC) in Calgary.

newborn screening

NMD4C Investigators Submit Response to CDA Draft Guidance on NBS

A group of NMD4C investigators recently submitted a response to the discussion paper from Canada’s Drug Agency outlining its approach for developing Canadian newborn screening guidance.